As part of the unique mCRPC phenotype in bone, several studies have shown prostate cancer cell lines secretion of BMPs can stimulate osteoblast cells in vitro to enhance matrix deposition or promote osteogenesis programs, both of which can be reversed with BMP inhibition (17, 18). This evidence concerns the gene CLN5 and prostate carcinoma.